1 Qualitative and quantitative composition
VOLTAREN Ophtha: one mL contains 1 mg of diclofenac sodium. For a full list of excipients, see List of excipients.

2 Pharmaceutical form
Eye drops, solution.

3 Clinical particulars

3.1 Therapeutic indications
Post-operative inflammation in cataract surgery and other surgical interventions.
Prevention of cystoid macular oedema after cataract extraction with lens implantation.
Post-traumatic inflammation in non-penetrating wounds.
Inhibition of miosis in cataract surgery.
Relief of pain and photophobia.
Non-infected inflammatory conditions of the anterior segment of the eye.

3.2 Dosage and method of administration

3.2.1 Adults
a) Ocular surgery and its complications
Preoperatively, up to 1 drop 5 times during the 3 hours before surgery.
Postoperatively, 1 drop 3 times on the day of surgery, followed by 1 drop 3 to 5 times daily for as long as required.
b) Relief of pain and photophobia; post-traumatic inflammation
One drop 4 to 6 hourly.
When pain is due to a surgical procedure (e.g. refractive surgery), 1 to 2 drops in the hour preceding surgery, 1 to 2 drops within the first 15 minutes after intervention and 1 drop 4 to 6 hourly for 3 days thereafter.

3.2.2 Elderly:
There is no indication that dosage needs to be modified for the elderly.

3.2.3 Paediatric use:
VOLTAREN Ophtha is not indicated for use in children. Paediatric experience is limited to a few published clinical studies in strabismus surgery.

3.2.4 Multiple Dose Unit (MDU):
The dispenser remains sterile until the original closure is broken. Patients must be instructed to avoid allowing the tip of the dispensing container to contact the eye or
surrounding structures as this may contaminate the solution.

3.2.5 Single Dose Unit (SDU):
The contents remain sterile until the original closure is broken. Patients must discard residual contents after use. If more than one medication needs to be instilled in the eye, an interval of at least 5 minutes between application of the different medicinal products must be allowed. Following instillation of the eye drops, nasolacrimal occlusion or closing the eyes for 3 minutes may reduce systemic absorption. This may result in a decrease in systemic side effects and an increase in local activity.

3.3 Contraindications
Known hypersensitivity to the active substance or to any of the excipients (see List of excipients).
As with other non-steroidal anti-inflammatory agents, VOLTAREN® Ophtha is contraindicated in patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or by other drugs with prostaglandin synthesis inhibiting activity. There is the potential for cross- sensitivity to aspirin, phenylacetic acid derivatives, and other non-steroidal anti-inflammatory agents.

3.4 Special warnings and precautions for use
The anti-inflammatory activity of ophthalmic non-steroidal anti-inflammatory agents (NSAIDs) including diclofenac may mask the onset and/or progression of ocular infections. In the presence of an infection or if there is a risk of infection, appropriate therapy should be given concurrently with VOLTARENS Ophtha.
Although there have been no reported adverse events, there is a theoretical possibility that patients receiving other medications which may prolong bleeding time, or with known haemostatic defects may experience exacerbation with VOLTAREN Ophtha.
Topical NSAIDs are known to slow or delay healing. Topical ophthalmic corticosteroids may slow corneal wound healing. Caution should be exercised when topical NSAIDs such as diclofenac are used concomitantly with topical steroids (see Interaction with other medicinal products and other forms of interaction).
Eye drops are not for injection. They should never be injected subconjunctivally, nor should they be directly introduced into the anterior chamber of the eye.
Patients with evidence of corneal epithelial breakdown should immediately discontinue use of VOLTAREN Ophtha eye drops and should be monitored closely for corneal health.
VOLTAREN Ophtha should not be used while wearing soft contact lenses. The lenses must be removed before application of the drops and not reinserted earlier than 15 minutes after use. The VOLTAREN Ophtha multiple dose unit formulation contains benzalkonium chloride as a preservative which may cause eye irritation and is known to discolour soft contact lenses.
The wearing of contact lenses is discouraged during treatment of an ocular inflammation.

3.5 Interaction with other medicinal products and other forms of interaction
Concomitant use of topical NSAIDs such as diclofenac and topical steroids in patients with
significant pre-existing corneal inflammation may increase the risk of developing corneal complications including slow or delay corneal healing, therefore caution should be used. Concomitant use of VOLTAREN® Ophtha eye drops with medications that prolong bleeding time may increase the risk of haemorrhage. Ocular diclofenac at 0.1% has been used safely in clinical studies in combination with antibiotics and beta-blocking agents for ocular use.

3.6 Fertility, Pregnancy and lactation

3.6.1 Fertility
Studies have not been performed to evaluate the effect of topical ocular administration of VOLTAREN Ophtha on human fertility. Animal studies suggest that prostaglandins are necessary for implantation. Therefore, long-term use of NSAIDs by prescription for chronic non-reproductive disorders and continuing use of over-the-counter NSAIDs preparations, while trying to conceive, could potentially adversely affect the peri-implantation process and outcome.

3.6.2 Pregnancy
No reproductive toxicity studies have been conducted with VOLTAREN Ophtha. Systemic diclofenac has been shown to cross the placental barrier in mice and rats, but had no influence on the fertility of parent animals in rats. There was no evidence that diclofenac had a teratogenic potential in routine mice, rat or rabbit embryo-foetal development studies. In rats, maternally toxic doses were associated with dystocia, prolonged gestation, decreased foetal survival, and intrauterine growth retardation. The slight effects of diclofenac on fertility and delivery as well as constriction of the ductus arteriosus in utero are pharmacological consequences of this class of prostaglandin synthesis inhibitors.

The prenatal, perinatal and postnatal development of the offspring were not affected. Animal studies have so far shown no risk to the foetus during the first and second trimesters of pregnancy, but no controlled studies in pregnant women are available. VOLTAREN Ophtha should not be used during the third trimester of pregnancy, due to possible risk of premature closure of the ductus arteriosus and possible inhibition of contractions.

3.6.3 Lactation
There is insufficient information on the excretion of diclofenac in human milk after the use of VOLTAREN Ophtha. Following oral administration of 50 mg coated tablets (content of 10.5 mL bottles of VOLTAREN Ophtha) only traces of the active substance were detected in breast milk and in quantities so small that no undesirable effects on the infant are to be expected. Use of ocular diclofenac is not recommended during breastfeeding unless the expected benefits outweigh the possible risks.

3.7 Effects on ability to drive and use machines
Patients experiencing blurred vision or other visual disturbances should refrain from driving a vehicle or operating machines until vision clears.

3.8 Adverse effects
The most frequently observed adverse reaction is a transient, mild to moderate eye
irritation.
Other less frequently observed reactions are eye pain, eye pruritus, ocular hyperaemia and blurred vision immediately after instillation of the eye drops.
Punctate keratitis or corneal disorders have been observed, usually after frequent application. In patients with risk factors of corneal disorders such as during the use of corticosteroids or with concomitant diseases such as infections or rheumatoid arthritis, diclofenac has been associated, in rare cases, with ulcerative keratitis, corneal thinning, punctate keratitis, corneal epithelium defect and corneal oedema, which might become sight-threatening. Most patients were treated for a prolonged period of time. In rare cases dyspnoea and exacerbation of asthma have been reported.
Allergic conditions has been reported such as conjunctival hyperaemia, allergic conjunctivitis, eyelid erythema, eye allergy, eyelid oedema, eyelid pruritus, urticaria, rash, eczema, erythema, pruritus, hypersensitivity, cough and rhinitis.

Post Marketing Experience
The following adverse reactions have been reported during Alcon clinical studies with VOLTAREN® Ophtha and are classified according to the subsequent convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Eye disorders
Common (≥ 1% to < 10%): punctate keratitis, eye pain, eye irritation, eye pruritus, conjunctival hyperaemia.
Uncommon (≥ 0.1% to < 1%): keratitis, intraocular pressure increased, corneal oedema, conjunctival oedema, corneal deposits, conjunctival follicles, ocular discomfort, eye discharge, eyelid margin crusting, lacrimation increased, eyelid irritation, ocular hyperaemia

Immune system disorders
Uncommon (≥ 0.1% to < 1%): hypersensitivity

General disorders and administration site conditions
Uncommon (≥ 0.1% to < 1%): impaired healing

The following adverse reactions have been identified from post-marketing surveillance following administration of VOLTAREN Ophtha. Frequency cannot be estimated from the available data. Within each System Organ Class adverse reactions are presented in order of decreasing seriousness.

Eye disorders
Not Known: corneal perforation, ulcerative keratitis, corneal epithelium defect, corneal opacity, corneal thinning, allergic conjunctivitis, eye allergy, eyelid erythema, eyelid oedema, eyelid pruritus, vision blurred.
Infections and infestations
Not Known: rhinitis

Respiratory, thoracic and mediastinal disorders
Not Known: asthma exacerbations, dyspnoea, cough

Skin and subcutaneous tissue disorders
Not Known: urticaria, rash, eczema, erythema, pruritus

3.9 Overdose
There is no experience of overdose with VOLTAREN® Ophtha. However, inadvertent oral ingestion carries a minimal risk of adverse effects as a single dose unit of VOLTAREN Ophtha contains only 0.3 mg diclofenac sodium and a multiple dose unit of VOLTAREN Ophtha contains only 5 mg diclofenac sodium, corresponding to about 0.2% and 3%, respectively, of the recommended maximum oral daily dose for an adult.

4 Pharmacological properties

4.1 Pharmacodynamic properties
Pharmacotherapeutic group: anti-inflammatory agents, non-steroids, ATC code: S01BC03
VOLTAREN Ophtha contains diclofenac sodium, a non-steroidal anti-inflammatory agent with analgesic properties. It has marked prostaglandin synthesis inhibitory activity and this is thought to have an important bearing on its mechanism of action.
Clinical trials have demonstrated that diclofenac inhibits miosis during cataract surgery and reduces ocular inflammation and pain associated with corneal epithelial defects after some types of surgical intervention.
There is no indication that diclofenac has any adverse effects on wound healing. VOLTAREN Ophtha multiple dose unit contains a cyclodextrin, hydroxypropyl gamma- cycloextrin (HPgamma-CD). Cyclodextrins (CDs) increase the aqueous solubility of some lipophilic water-insoluble drugs. It is believed that CDs act as true carriers by keeping hydrophobic drug molecules in solution and delivering them to the surface of biological membranes.

4.2 Pharmacokinetic properties
In rabbits, peak concentrations of 14C-labelled diclofenac could be demonstrated in the cornea and conjunctiva 30 minutes after application. Elimination was rapid and almost complete after 6 hours.
Concentrations of HP-gamma-CD in plasma and aqueous humor were below detection limits (1 nMol/mL) in rabbits after single or four times daily (q.i.d.) ocular administration for 28 days. Low concentrations of HP-gamma-CD were detected in the aqueous humor of two rabbits (1 after single instillation, 1 after q.i.d. instillation for 28 days).
Penetration of diclofenac into the anterior chamber has been confirmed in humans. No measurable plasma levels of diclofenac could be found after ocular application of VOLTAREN® Ophtha, which contains 0.1% diclofenac.
4.3 Preclinical safety data
Preclinical data of systemically applied diclofenac from acute and repeated dose toxicity studies, as well as from genotoxicity, mutagenicity, teratogenicity, carcinogenicity and reproductive performance studies revealed no specific hazard for humans at the intended therapeutic doses. Systemic diclofenac has been shown to cross the placental barrier in mice and rats, but had no influence on the fertility of parent animals in rats. In rats, maternally toxic doses were associated with dystocia, prolonged gestation, decreased foetal survival, and intrauterine growth retardation. The slight effects of diclofenac on fertility and delivery as well as constriction of the ductus arteriosus in utero are pharmacological consequences of this class of prostaglandin synthesis inhibitors.
Local ocular tolerance and toxicity of different formulations of VOLTAREN Ophtha were investigated and no evidence of toxicity and local adverse effects was found.

4.3.1.1 Voltaren Ophtha Multiple Dose Unit (MDU):
The potential for local ocular toxicity and associated systemic toxicity of VOLTAREN Ophtha MDU and HPgamma-CD were investigated in a series of ocular tolerance studies in rabbits. In these studies the rabbits received up to 8 instillations of 25 microlitres of solution into the conjunctival sac of the right eye each day for up to 13 weeks. The left eye was untreated and provided a control for local effects in the treated right eye. The animals received either VOLTAREN Ophtha MDU with or without benzalkonium chloride or a formulation containing all of the excipients in VOLTAREN Ophtha MDU but containing 0.1% diclofenac potassium (instead of 0.1% diclofenac sodium) as the active ingredient or a 2% solution of HPgamma-CD in saline solution. In none of the studies was there any evidence of local adverse effects detectable by detailed ophthalmological and ocular histological examinations. There was no evidence of systemic effects in the haematology, clinical chemistry, urinalysis parameters or in the histological examination of the liver, lungs and kidneys.

5 Pharmaceutical particulars

5.1 List of excipients
5.1.1.1 Multiple dose unit:
Benzalkonium chloride; Disodium edetate; Hydroxypropyl gamma-cyclodextrin; Hydrochloric acid; Propylene glycol; Trometamol; Tyloxapol; Water for injections.

5.1.1.2 Unpreserved single dose units:
Polyoxyl 35 castor oil (cremophor EL), Boric acid, Trometamol, Water for injections.

5.2 Incompatibilities
None known.
5.3 Shelf life
5.3.1.1 Multidose formulation
2 years.
5.3.1.2 Unpreserved single dose units.
3 years.

5.4 Special precautions for storage
5.4.1.1 Multiple dose unit
Store below 25°C. The contents of the bottle should be discarded four weeks after opening.
5.4.1.2 Unpreserved single dose units
Store at 2°C to 8°C (refrigerate, do not freeze). After opening an inner blister, the contents are stable for one month when stored below 25°C. Discard each single dose unit immediately after use. Do not save contents.
VOLTAREN® Ophtha must be kept out of the reach and sight of children.

5.5 Nature and contents of container
5.5.1.1 Multiple dose unit
The product is presented in a 5 mL white-coloured LDPE bottle fitted with a LDPE dropper and a HDPE closure.
5.5.1.2 Unpreserved single dose units
LDPE block containing 5 Single Dose Units filled with 0.3 ml of eye drops each. Boxes of 30 single dose units.

5.6 Instructions for use and handling, and disposal
No special requirements.

5.7 Further Information
5.7.1.1 Chemical structure

5.8 Medicine classification
Prescription Medicine

5.9 Name and Address
Alcon Laboratories (Australia) Pty Ltd
25 Frenchs Forest Road East
Frenchs Forest NSW 2086
In New Zealand this product is distributed by: Pharmaco (NZ) Ltd
4 Fisher Crescent
Auckland 1060
New Zealand
Free Phone: 0800 101 106

5.10 Date of preparation
17 November 2015